Navigation Links
Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
Date:9/25/2008

NEW YORK, Sept. 25 /PRNewswire/ -- Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) announced that notification was received today that its patent application entitled, "Low Oxygen Organic Waste Bioconversion System" has been granted by the Commonwealth of Australia Patent Office and given a Standard Patent number of 2002227224. The official filing date is approved as November 8, 2001 and the patent will be in force until an expiration date of November 8, 2021.

This patent now fully protects the core Bion process as applied in all Bion Environmental Management System configurations in this important livestock and dairy production country. Bion's international intellectual property protection currently includes issued patents in the key markets of Canada, Mexico, New Zealand and now Australia. In addition Bion has patents pending in the entire European Union, Brazil, and Argentina.

About Bion: Bion has provided solutions to the agriculture and livestock industry since 1990, with 30 first-generation systems installed through 2003. Bion's next-generation technology results from 18 years of research & development, testing, commercial deployment, and further adaptation to evolving standards and opportunities. In addition to providing proven comprehensive environmental treatment, the system recovers cellulosic biomass from the waste stream to produce renewable energy in a process different and much more efficient than others that seek to exploit this energy source. The technology is scalable, proven and quickly gaining acceptance by regulatory agencies and other stakeholders as an effective solution to the environmental issues associated with concentrated livestock waste. For more information, see Bion's website: http://www.biontech.com.

This material includes forward-looking statements based on management's current reasonable business expectations. In this document, the word '
'/>"/>

SOURCE Bion Environmental Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 /PRNewswire/ ... a leader in synthetic biology, today announced it has ... (OSF), the pioneering agricultural company behind the ... apple. Through the acquisition, Intrexon expands its food programs ... and convenient for consumers while providing economic benefit throughout ...
(Date:2/27/2015)... , Feb. 27, 2015 A paper ... NCATS rare-diseases portfolio " in Science Translational ... financing technique to reduce the risk associated with ... potentially unlock new levels of funding for developing ... of a unique collaboration between scientists at the ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... Corporation,(Nasdaq: KNSY ) will present at the ... Forum at The Ritz-Carlton San Francisco on,Tuesday, September ... President & CEO, will deliver the,Company,s presentation, beginning ... be available on the company,s website,( http://www.kenseynash.com ) ...
... Calif., Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ), a ... effective drugs in the areas of women,s health and,cancer, announced ... presenting at A.G. Edwards, 2nd Annual Emerging Growth Conference in ... AM ET on Tuesday,September 18, 2007 at the New York ...
... AT 10:00AM EDT, EDMONTON, BELLEVUE, WASHINGTON, Sept. ... (TSX: BRA) (the "Company") today announced that,the Company,s ... change its,jurisdiction of incorporation from the federal jurisdiction ... United States of America through a plan of,arrangement. ...
Cached Biology Technology:Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference 2Bionovo to Present at A.G. Edwards' 2nd Annual Emerging Growth Conference 2007 2Biomira Announces Plan to Reincorporate in the United States 2Biomira Announces Plan to Reincorporate in the United States 3Biomira Announces Plan to Reincorporate in the United States 4Biomira Announces Plan to Reincorporate in the United States 5Biomira Announces Plan to Reincorporate in the United States 6
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Minnesota Partnership for Biotechnology and Medical Genomics announced ... 2013 Discovery Transformation Grant Program. Together, the selected ... to support their work in diabetes research. Minnesota ... Minnesota Legislature With an eye on funding ...
... genome in human lung cells will ensure safe research on ... of Medicine at Mount Sinai. Details of their "molecular ... to humans, are published in Nature Biotechnology . ... in human lung cells to latch on to these viruses ...
... Swiss men prefer beer when they drink alcohol, taking in ... form of the beverage. Far fewer (around five percent) prefer ... alcoholic beverages and a riskier approach to alcohol or other ... and Preventive Medicine at the University of Zurich and Lausanne ...
Cached Biology News:4 projects awarded Discovery Transformation Grant funding by Minnesota Partnership 24 projects awarded Discovery Transformation Grant funding by Minnesota Partnership 3Scientists develop method that ensures safe research on deadly flu viruses 2Scientists develop method that ensures safe research on deadly flu viruses 3Young beer-drinkers binge-drink more frequently 2
... ProFound Label Transfer Sulfo SBED Protein:Protein Interaction ... as Label Transfer has rapidly gained traction ... interaction discovery. A growing number of publications ... Label Transfer Reagent to study a variety ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
Biology Products: